Other medical trials in patients with non-Hodgkin's lymphoma [24] and clients with Innovative malignancy [fourteen] have demonstrated also that zosuquidar didn't substantially have an effect on the pharmacokinetics of doxorubicin and experienced moderate outcomes around the pharmacokinetics of vincristine. These clinical trials approved that zosuquidar could safely administrated with ... https://vonp887ber8.wikifordummies.com/user